Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1164P (*RNA, U6 small nuclear 1164, pseudogene*) is a processed pseudogene derived from the U6 small nuclear RNA (snRNA) locus in the human genome, and it is not considered a bona fide therapeutic target or receptor. RNU6-1164P represents a segment of the human genome classified as a pseudogene derived from the highly conserved U6 small nuclear RNA (snRNA) locus[4][2]. U6 snRNA itself is an essential, noncoding RNA component of the spliceosome, a ribonucleoprotein complex that catalyzes pre-mRNA splicing in eukaryotic cells[3][1]. However, pseudogenes like RNU6-1164P are genomic copies that have lost the ability to encode functional RNA due to sequence mutations, truncations, or duplications, and are typically generated through retrotransposition mechanisms, mainly mediated by LINE-1 (L1) elements[2][5]. These pseudogenes do not participate in the biological functions of their parent genes such as splicing or RNA modification, nor do they serve as drug targets or biomarkers. The reference to "1164" is a genomic identifier for the specific pseudogene, not a unique biological entity. Key points: - RNU6-1164P is a processed pseudogene—it does not produce functional snRNA nor participate in cellular splicing processes[2][4][5]. - U6 snRNA is essential for catalysis in the spliceosome, but pseudogenes of U6 (including RNU6-1164P) are genomic relics and not active molecules[3][1]. - Not a therapeutic target—no interacting drugs, mechanism of action, or clinical relevance described. - Frequently misinterpreted—while U6 snRNA is functionally critical, RNU6-1164P is not, and listings of "RNU6-1164P" as a molecular target are misleading or incorrect for biomedical purposes. *If you require information on the functional U6 snRNA itself (not the pseudogene), this is an essential RNA component of the spliceosome for pre-mRNA splicing, but RNU6-1164P should not be considered a target for drug discovery or therapeutic interventions.*
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1164, pseudogene (RNU6-1164P).